CPC Scientific’s Tirzepatide API Successfully Secures US FDA DMF Filing
CPC Scientific, a premier peptide and oligonucleotide-focused CRDMO and a wholly owned subsidiary of Medtide Inc. (HKEX: 3880.HK), today announced that its Hangzhou-based CGMP manufacturing facility, Chinese Peptide Company, has successfully completed the Drug Master File (DMF) filing for its self-developed Tirzepatide active pharmaceutical ingredient (API) with the U.S. Food and Drug Administration (FDA) under DMF number 043979.



